Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous tumor RNA-loaded dendritic cell vaccine
- Development stage
- Unknown
- Lead developer
- Radboud University Medical Center
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intravenous, Intradermal
01
Overview
The autologous tumor RNA-loaded dendritic cell vaccine is an investigational, patient-specific cellular immunotherapy developed by Radboud University Medical Centre. It consists of autologous monocyte-derived dendritic cells that are electroporated or pulsed with total RNA extracted from the patient's own tumor cells. This approach allows the dendritic cells to present a comprehensive array of tumor-associated antigens to the patient's immune system, aiming to stimulate a T-cell-mediated antitumor response. The vaccine is primarily evaluated in patients with multiple myeloma who have minimal residual disease (MRD) following autologous stem cell transplantation.
- Other names
- RNA-loaded dendritic cell vaccineautologous dendritic cells loaded with tumor RNA
02
Targets
pMHCII (Tumor-derived peptide–Major Histocompatibility Complex class II complex)pMHC-I (Tumor-derived peptide–major histocompatibility complex class I)CD28 (Cluster of Differentiation 28)
Beyond the preview
Go deeper on autologous tumor RNA-loaded dendritic cell vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous tumor RNA-loaded dendritic cell vaccine.